Navigation Links
EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting

Supports Local Mechanism of Action of NP-1 in Neuropathic Pain

TARRYTOWN, N.Y., May 03, 2007 /PRNewswire-FirstCall/ -- EpiCept Corporation announced today that it will present new data for EpiCept(TM) NP-1 on Thursday, May 3, 2007 at the 26th Annual Scientific Meeting of the American Pain Society in Washington D.C. EpiCept NP-1 is a patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine. NP-1 is a product candidate intended for use in the management of pain resulting from various peripheral neuropathies. Two studies will be presented in poster format by Dennis Everton, RPh., Director of Clinical Development.

Results from a new human pharmacokinetic study of NP-1 designed to assess the pharmacokinetic parameters as well as its safety and tolerability will be presented. The highest observed level of amitriptyline at any time point was 5.91 ng/mL. The highest observed level of ketamine at any time point was 10.7 ng/mL. These levels are far below any known systemic efficacy level and even further below any known systemic level associated with adverse reactions. The study found that NP-1 was safe and well tolerated across all age groups studied. The low systemic levels of amitriptyline and ketamine indicated a local mechanism of action rather than a systemic one. NP-1 is intended as additive therapy in neuropathic pain. This study confirms the independent topical mechanism of NP-1.

Findings will also be presented from a previously disclosed multicenter, double-blind, randomized, placebo controlled Phase II study of NP-1 in treating post-herpetic neuralgia (PHN) in 118 patients. The study was designed to evaluate the analgesic properties of two different strengths of NP-1 compared with placebo in the treatment of PHN. The study met its primary endpoint of an improvement in pain intensity for the high dose strength vs. placebo from baseline to day 21 (p=0.026). Add
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. The Past, Present and Future of HLA Typing
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... VICL ) today announced the receipt of ... for costs associated with the ongoing Allovectin-7(R),Immunotherapeutic for ... is funding the Phase 3 pivotal trial of ... scheduled series of,cash payments and equity investments totaling ...
... Atrial ... Fibrillation Patients, CARLSBAD, Calif., Jan. 16 ... ever U.S.,Investigational Device Exemption (IDE) clinical trial for interventional,treatment of chronic ... to proceed with the pivotal phase of the,study is based on ...
Cached Medicine Technology:Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 2Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 3FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 2FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 Smile Squared, ... their product offering to include a US-made toothbrush. For ... child without one. , “Smile Squared was created by ... clinic in Guatemala,” said Eric Cope, President of Smile ... sometimes severe dental problems. But many of the same ...
(Date:9/2/2014)... Spain Tuesday 2 September 2014: Digoxin may increase ... (AF) by approximately 20%, according to results from the ... Dr Manesh Patel, director of interventional cardiology and catheterisation ... Carolina, US. The findings suggest that caution may be ... further studies are needed to confirm the observations. , ...
(Date:9/2/2014)... The fact that mechanical heart valves increase risks during ... the ROPAC registry presented for the first time today ... Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall of ... of pregnant women with a mechanical heart valve died ... Registry Of Pregnancy And Cardiac disease (ROPAC) is an ...
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and home medical ... of its new office to be located in Greer, ... Suite D, Greer, SC 29651. This new location will ... convenient location in the Greenville area. , “This is ... hospitals and patients we serve, to ensure that we ...
(Date:9/2/2014)... 2014 Attorney Robert M. Higgins ... of the Year" for Medical Malpractice Law - ... Boston, and has been selected for inclusion in The Best ... in each practice area and designated metropolitan area is honored ... voting averages received during the peer-review assessments. , The ...
Breaking Medicine News(10 mins):Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2
... the process of developing a vaccine called Gardasil against ... is being sought by the organization in Europe and ... MSD has to approve of the marketing authorization for ... to have a decided advantage over GlaxoSmithKline’s Cervarix. Both ...
... (PCRM) has developed an in-house animal serum free diabetes test ... by Linco Research. PCRM started to initiate the development of ... that it is not possible to develop the test kit ... kit uses synthetic medium and the cost and accuracy is ...
... treated with 500 mcg of Aranesp (Darbepoetin alfa) for ... in 70% of patients. //The new drug Aranesp is ... trial with 200 low-risk MDS patients who were administered ... is a pre-leukemia stage in which the bone marrow ...
... conducted by George S. Zubenko, MD, PhD, Professor of Psychiatry ... that genes relating to aging with preserved mental capacity have ... kind and was funded by National Institutes of Health (NIH). ... years old or above. There were equal number of men ...
... Botulinum toxin A or Botox as it is popularly tagged ... for erasing wrinkles and making the facial skin appear fresh ... of Cosmetic Dermatology says that there is more to botox ... BTXA as it is called in medical parlance can also ...
... body thinking that it will fetch happiness. A study has ... mental suffering and woes, and they are far from being ... chances of slim people committing suicide appear to be greater ... ,The research was also extended to studying the European population, ...
Cached Medicine News:Health News:Genetics of Ageing with Preserved Mental Capacity. 2
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medicine Products: